{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:02:03Z","timestamp":1793246523075,"version":"4.5.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG058063"],"award-info":[{"award-number":["R01 AG058063"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54- CA225088-02S1"],"award-info":[{"award-number":["U54- CA225088-02S1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clinical trials of novel therapeutics for Alzheimer\u2019s Disease (AD) have consumed a large amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA) for another indication is a more rapid and less expensive option. We present DRIAD (Drug Repurposing In AD), a machine learning framework that quantifies potential associations between the pathology of AD severity (the Braak stage) and molecular mechanisms as encoded in lists of gene names. DRIAD is applied to lists of genes arising from perturbations in differentiated human neural cell cultures by 80 FDA-approved and clinically tested drugs, producing a ranked list of possible repurposing candidates. Top-scoring drugs are inspected for common trends among their targets. We propose that the DRIAD method can be used to nominate drugs that, after additional validation and identification of relevant pharmacodynamic biomarker(s), could be readily evaluated in a clinical trial.<\/jats:p>","DOI":"10.1038\/s41467-021-21330-0","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T09:31:41Z","timestamp":1613554301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":271,"title":["Machine learning identifies candidates for drug repurposing in Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Steve","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8299-3274","authenticated-orcid":false,"given":"Clemens","family":"Hug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4835-0643","authenticated-orcid":false,"given":"Petar","family":"Todorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6038-6863","authenticated-orcid":false,"given":"Nienke","family":"Moret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3118-3378","authenticated-orcid":false,"given":"Sarah A.","family":"Boswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1345-2634","authenticated-orcid":false,"given":"George","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2952-6730","authenticated-orcid":false,"given":"Nathan T.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-9401","authenticated-orcid":false,"given":"Bradley T.","family":"Hyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3364-1838","authenticated-orcid":false,"given":"Peter K.","family":"Sorger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7855-3455","authenticated-orcid":false,"given":"Mark W.","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-0504","authenticated-orcid":false,"given":"Artem","family":"Sokolov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"21330_CR1","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","volume":"80","author":"LE Hebert","year":"2013","unstructured":"Hebert, L. E., Weuve, J., Scherr, P. A. & Evans, D. A. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 80, 1778\u20131783 (2013).","journal-title":"Neurology"},{"key":"21330_CR2","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association. 2019 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 15, 321\u2013387 (2019).","DOI":"10.1016\/j.jalz.2019.01.010"},{"key":"21330_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","volume":"26","author":"D Mehta","year":"2017","unstructured":"Mehta, D., Jackson, R., Paul, G., Shi, J. & Sabbagh, M. Why do trials for Alzheimer\u2019s disease drugs keep failing? A discontinued drug perspective for 2010\u20132015. Expert Opin. Investig. Drugs 26, 735\u2013739 (2017).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"21330_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"21330_CR5","doi-asserted-by":"crossref","unstructured":"Hernandez, J. J. et al. Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front. Oncol. 7, 273 (2017).","DOI":"10.3389\/fonc.2017.00273"},{"key":"21330_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ebiom.2016.11.020","volume":"14","author":"V Mallikarjun","year":"2016","unstructured":"Mallikarjun, V. & Swift, J. Therapeutic manipulation of ageing: repurposing old dogs and discovering new tricks. EBioMedicine 14, 24\u201331 (2016).","journal-title":"EBioMedicine"},{"key":"21330_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1212\/WNL.0000000000006745","volume":"92","author":"Y Hara","year":"2019","unstructured":"Hara, Y., McKeehan, N. & Fillit, H. M. Translating the biology of aging into novel therapeutics for Alzheimer disease. Neurology 92, 84\u201393 (2019).","journal-title":"Neurology"},{"key":"21330_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.csbj.2016.10.003","volume":"15","author":"AJ Nevado-Holgado","year":"2017","unstructured":"Nevado-Holgado, A. J. & Lovestone, S. Determining the molecular pathways underlying the protective effect of non-steroidal anti-inflammatory drugs for Alzheimer\u2019s disease: a bioinformatics approach. Comput. Struct. Biotechnol. J. 15, 1\u20137 (2017).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"21330_CR9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrd3869","volume":"11","author":"A Corbett","year":"2012","unstructured":"Corbett, A. et al. Drug repositioning for Alzheimer\u2019s disease. Nat. Rev. Drug Discov. 11, 833\u2013846 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"21330_CR10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2174\/1389200218666170607101622","volume":"18","author":"M Shoaib","year":"2017","unstructured":"Shoaib, M., Kamal, M. A. & Rizvi, S. M. D. Repurposed drugs as potential therapeutic candidates for the management of Alzheimer\u2019s disease. Curr. Drug Metab. 18, 842\u2013852 (2017).","journal-title":"Curr. Drug Metab."},{"key":"21330_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/jamia\/ocw142","volume":"24","author":"AS Brown","year":"2017","unstructured":"Brown, A. S. & Patel, C. J. MeSHDD: literature-based drug-drug similarity for drug repositioning. J. Am. Med. Inform. Assoc. 24, 614\u2013618 (2017).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"21330_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/msb.2011.26","volume":"7","author":"A Gottlieb","year":"2011","unstructured":"Gottlieb, A., Stein, G. Y., Ruppin, E. & Sharan, R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol. Syst. Biol. 7, 496 (2011).","journal-title":"Mol. Syst. Biol."},{"key":"21330_CR13","doi-asserted-by":"crossref","unstructured":"Himmelstein, D. S. et al. Systematic integration of biomedical knowledge prioritizes drugs for repurposing. eLife 6, e26726 (2017).","DOI":"10.7554\/eLife.26726"},{"key":"21330_CR14","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929\u20131935 (2006).","journal-title":"Science"},{"key":"21330_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05116-5","volume":"9","author":"F Cheng","year":"2018","unstructured":"Cheng, F. et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat. Commun. 9, 2691 (2018).","journal-title":"Nat. Commun."},{"key":"21330_CR16","doi-asserted-by":"crossref","unstructured":"Zhang, M. et al. Drug repositioning for Alzheimer\u2019s disease based on systematic \u2018omics\u2019 data mining. PLoS ONE 11, e0168812 (2016).","DOI":"10.1371\/journal.pone.0168812"},{"key":"21330_CR17","doi-asserted-by":"publisher","unstructured":"Regan, K., Moosavinasab, S., Payne, P. & Lin, S. Drug repurposing hypothesis generation using the \u2018RE:fine Drugs\u2019 System. J. Vis. Exp. https:\/\/doi.org\/10.3791\/54948 (2016).","DOI":"10.3791\/54948"},{"key":"21330_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fpubh.2018.00181","volume":"6","author":"J Ryan","year":"2018","unstructured":"Ryan, J., Fransquet, P., Wrigglesworth, J. & Lacaze, P. Phenotypic heterogeneity in dementia: a challenge for epidemiology and biomarker studies. Front. Public Health 6, 181 (2018).","journal-title":"Front. Public Health"},{"key":"21330_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/ana.25380","volume":"85","author":"PA Boyle","year":"2019","unstructured":"Boyle, P. A. et al. Attributable risk of Alzheimer\u2019s dementia attributed to age-related neuropathologies. Ann. Neurol. 85, 114\u2013124 (2019).","journal-title":"Ann. Neurol."},{"key":"21330_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1517\/14728222.2016.1135132","volume":"20","author":"RJ Hodes","year":"2016","unstructured":"Hodes, R. J. & Buckholtz, N. Accelerating medicines partnership: Alzheimer\u2019s Disease (AMP-AD) Knowledge Portal aids Alzheimer\u2019s drug discovery through open data sharing. Expert Opin. Ther. Targets 20, 389\u2013391 (2016).","journal-title":"Expert Opin. Ther. Targets"},{"key":"21330_CR21","doi-asserted-by":"publisher","first-page":"e12819","DOI":"10.1111\/acel.12819","volume":"17","author":"HM D\u00f6nerta\u015f","year":"2018","unstructured":"D\u00f6nerta\u015f, H. M., Fuentealba Valenzuela, M., Partridge, L. & Thornton, J. M. Gene expression-based drug repurposing to target aging. Aging Cell 17, e12819 (2018).","journal-title":"Aging Cell"},{"key":"21330_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0555-x","volume":"9","author":"G Williams","year":"2019","unstructured":"Williams, G. et al. Drug repurposing for Alzheimer\u2019s disease based on transcriptional profiling of human iPSC-derived cortical neurons. Transl. Psychiatry 9, 220 (2019).","journal-title":"Transl. Psychiatry"},{"key":"21330_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/npjsba.2016.15","volume":"2","author":"Q Duan","year":"2016","unstructured":"Duan, Q. et al. L1000CDS 2: LINCS L1000 characteristic direction signatures search engine. NPJ Syst. Biol. Appl. 2, 1\u201312 (2016).","journal-title":"NPJ Syst. Biol. Appl."},{"key":"21330_CR24","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1093\/bioinformatics\/bty060","volume":"34","author":"Z Wang","year":"2018","unstructured":"Wang, Z., Lachmann, A., Keenan, A. B. & Ma\u2019ayan, A. L1000FWD: fireworks visualization of drug-induced transcriptomic signatures. Bioinformatics 34, 2150\u20132152 (2018).","journal-title":"Bioinformatics"},{"key":"21330_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-biodatasci-072018-021211","volume":"2","author":"AB Keenan","year":"2019","unstructured":"Keenan, A. B. et al. Connectivity Mapping: methods and applications. Annu. Rev. Biomed. Data Sci. 2, 69\u201392 (2019).","journal-title":"Annu. Rev. Biomed. Data Sci."},{"key":"21330_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathol."},{"key":"21330_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.chembiol.2019.02.018","volume":"26","author":"N Moret","year":"2019","unstructured":"Moret, N. et al. Cheminformatics tools for analyzing and designing optimized small-molecule collections and libraries. Cell Chem. Biol. 26, 765\u2013777.e3 (2019).","journal-title":"Cell Chem. Biol."},{"key":"21330_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long, J. M. & Holtzman, D. M. Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179, 312\u2013339 (2019).","journal-title":"Cell"},{"key":"21330_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejmech.2017.07.070","volume":"139","author":"M Jouanne","year":"2017","unstructured":"Jouanne, M., Rault, S. & Voisin-Chiret, A.-S. Tau protein aggregation in Alzheimer\u2019s disease: an attractive target for the development of novel therapeutic agents. Eur. J. Med. Chem. 139, 153\u2013167 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"21330_CR30","doi-asserted-by":"crossref","unstructured":"Li, X., Long, J., He, T., Belshaw, R. & Scott, J. Integrated genomic approaches identify major pathways and upstream regulators in late onset Alzheimer\u2019s disease. Sci. Rep. 5, 12393 (2015).","DOI":"10.1038\/srep12393"},{"key":"21330_CR31","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1523\/JNEUROSCI.4098-07.2008","volume":"28","author":"JA Miller","year":"2008","unstructured":"Miller, J. A., Oldham, M. C. & Geschwind, D. H. A systems level analysis of transcriptional changes in Alzheimer\u2019s disease and normal aging. J. Neurosci. 28, 1410\u20131420 (2008).","journal-title":"J. Neurosci."},{"key":"21330_CR32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cels.2016.11.006","volume":"4","author":"NT Seyfried","year":"2017","unstructured":"Seyfried, N. T. et al. A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer\u2019s disease. Cell Syst. 4, 60\u201372.e4 (2017).","journal-title":"Cell Syst."},{"key":"21330_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-6-52","volume":"6","author":"S Mizuno","year":"2012","unstructured":"Mizuno, S. et al. AlzPathway: a comprehensive map of signaling pathways of Alzheimer\u2019s disease. BMC Syst. Biol. 6, 52 (2012).","journal-title":"BMC Syst. Biol."},{"key":"21330_CR34","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41593-018-0154-9","volume":"21","author":"S Mostafavi","year":"2018","unstructured":"Mostafavi, S. et al. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer\u2019s disease. Nat. Neurosci. 21, 811\u2013819 (2018).","journal-title":"Nat. Neurosci."},{"key":"21330_CR35","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jalz.2017.09.012","volume":"14","author":"M Allen","year":"2018","unstructured":"Allen, M. et al. Conserved brain myelination networks are altered in Alzheimer\u2019s and other neurodegenerative diseases. Alzheimers Dement. 14, 352\u2013366 (2018).","journal-title":"Alzheimers Dement."},{"key":"21330_CR36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-018-1900-5","volume":"136","author":"M Allen","year":"2018","unstructured":"Allen, M. et al. Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy. Acta Neuropathol. 136, 709\u2013727 (2018).","journal-title":"Acta Neuropathol."},{"key":"21330_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0530-9","volume":"10","author":"M Sekiya","year":"2018","unstructured":"Sekiya, M. et al. Integrated biology approach reveals molecular and pathological interactions among Alzheimer\u2019s A\u03b242, Tau, TREM2, and TYROBP in Drosophila models. Genome Med. 10, 26 (2018).","journal-title":"Genome Med."},{"key":"21330_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0355-3","volume":"8","author":"M Wang","year":"2016","unstructured":"Wang, M. et al. Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer\u2019s disease. Genome Med. 8, 104 (2016).","journal-title":"Genome Med."},{"key":"21330_CR39","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/s41588-018-0238-1","volume":"50","author":"T Raj","year":"2018","unstructured":"Raj, T. et al. Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer\u2019s disease susceptibility. Nat. Genet. 50, 1584\u20131592 (2018).","journal-title":"Nat. Genet."},{"key":"21330_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13024-017-0219-3","volume":"12","author":"AT McKenzie","year":"2017","unstructured":"McKenzie, A. T. et al. Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer\u2019s disease. Mol. Neurodegener. 12, 82 (2017).","journal-title":"Mol. Neurodegener."},{"key":"21330_CR41","doi-asserted-by":"publisher","first-page":"E1289","DOI":"10.1073\/pnas.1710329115","volume":"115","author":"RE Bennett","year":"2018","unstructured":"Bennett, R. E. et al. Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer\u2019s disease. Proc. Natl Acad. Sci. USA 115, E1289\u2013E1298 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21330_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118\u2013127 (2007).","journal-title":"Biostatistics"},{"key":"21330_CR43","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1371\/journal.pgen.0030161","volume":"3","author":"JT Leek","year":"2007","unstructured":"Leek, J. T. & Storey, J. D. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 3, e161 (2007).","journal-title":"PLoS Genet."},{"key":"21330_CR44","unstructured":"Gagnon-Bartsch, J. A., Jacob, L. & Speed, T. P. Removing Unwanted Variation From High Dimensional Data With Negative Controls. Berkeley Technical Report 1\u2013112 (Department of Statistics, University of California, 2013)."},{"key":"21330_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2019.16","volume":"6","author":"Y Song","year":"2019","unstructured":"Song, Y. et al. A dynamic view of the proteomic landscape during differentiation of ReNcell VM cells, an immortalized human neural progenitor line. Sci. Data 6, 190016 (2019).","journal-title":"Sci. Data"},{"key":"21330_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-02088-w","volume":"9","author":"C Ye","year":"2018","unstructured":"Ye, C. et al. DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery. Nat. Commun. 9, 1\u20139 (2018).","journal-title":"Nat. Commun."},{"key":"21330_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"21330_CR48","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1073\/pnas.1814092116","volume":"116","author":"DJ Wilson","year":"2019","unstructured":"Wilson, D. J. The harmonic mean p-value for combining dependent tests. Proc. Natl Acad. Sci. USA 116, 1195\u20131200 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21330_CR49","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1021\/jm400402q","volume":"56","author":"TH Marsilje","year":"2013","unstructured":"Marsilje, T. H. et al. Synthesis, structure\u2013activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J. Med. Chem. 56, 5675\u20135690 (2013).","journal-title":"J. Med. Chem."},{"key":"21330_CR50","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.chembiol.2019.05.005","volume":"26","author":"M Hafner","year":"2019","unstructured":"Hafner, M. et al. Multiomics profiling establishes the polypharmacology of FDA-approved CDK4\/6 inhibitors and the potential for differential clinical activity. Cell Chem. Biol. 26, 1067\u20131080.e8 (2019).","journal-title":"Cell Chem. Biol."},{"key":"21330_CR51","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00702-017-1745-4","volume":"125","author":"JM Taylor","year":"2018","unstructured":"Taylor, J. M., Moore, Z., Minter, M. R. & Crack, P. J. Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer\u2019s disease. J. Neural Transm. (Vienna) 125, 797\u2013807 (2018).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"21330_CR52","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/emboj.2010.338","volume":"30","author":"H-W Tang","year":"2011","unstructured":"Tang, H.-W. et al. Atg1-mediated myosin II activation regulates autophagosome formation during starvation-induced autophagy. EMBO J. 30, 636\u2013651 (2011).","journal-title":"EMBO J."},{"key":"21330_CR53","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1042\/EBC20170021","volume":"61","author":"M Zachari","year":"2017","unstructured":"Zachari, M. & Ganley, I. G. The mammalian ULK1 complex and autophagy initiation. Essays Biochem. 61, 585\u2013596 (2017).","journal-title":"Essays Biochem."},{"key":"21330_CR54","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4161\/auto.7.7.15450","volume":"7","author":"E-J Lee","year":"2011","unstructured":"Lee, E.-J. & Tournier, C. The requirement of uncoordinated 51-like kinase 1 (ULK1) and ULK2 in the regulation of autophagy. Autophagy 7, 689\u2013695 (2011).","journal-title":"Autophagy"},{"key":"21330_CR55","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1515\/revneuro-2014-0076","volume":"26","author":"A Zare-Shahabadi","year":"2015","unstructured":"Zare-Shahabadi, A., Masliah, E., Johnson, G. V. W. & Rezaei, N. Autophagy in Alzheimer\u2019s disease. Rev. Neurosci. 26, 385\u2013395 (2015).","journal-title":"Rev. Neurosci."},{"key":"21330_CR56","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/msj.20161","volume":"77","author":"SF Funderburk","year":"2010","unstructured":"Funderburk, S. F., Marcellino, B. K. & Yue, Z. Cell \u2018self-eating\u2019 (autophagy) mechanism in Alzheimer\u2019s disease. Mt. Sinai J. Med. 77, 59\u201368 (2010).","journal-title":"Mt. Sinai J. Med."},{"key":"21330_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-018-0364-9","volume":"11","author":"KS Abd-Elrahman","year":"2018","unstructured":"Abd-Elrahman, K. S., Hamilton, A., Vasefi, M. & Ferguson, S. S. G. Autophagy is increased following either pharmacological or genetic silencing of mGluR5 signaling in Alzheimer\u2019s disease mouse models. Mol. Brain 11, 19 (2018).","journal-title":"Mol. Brain"},{"key":"21330_CR58","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.neulet.2019.04.045","volume":"705","author":"L Wang","year":"2019","unstructured":"Wang, L., Jin, G., Yu, H., Li, Q. & Yang, H. Protective effect of Tenuifolin against Alzheimer\u2019s disease. Neurosci. Lett. 705, 195\u2013201 (2019).","journal-title":"Neurosci. Lett."},{"key":"21330_CR59","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/glia.23572","volume":"67","author":"A Patir","year":"2019","unstructured":"Patir, A., Shih, B., McColl, B. W. & Freeman, T. C. A core transcriptional signature of human microglia: Derivation and utility in describing region-dependent alterations associated with Alzheimer\u2019s disease. Glia 67, 1240\u20131253 (2019).","journal-title":"Glia"},{"key":"21330_CR60","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12031-017-0969-y","volume":"63","author":"EM Ellison","year":"2017","unstructured":"Ellison, E. M., Bradley-Whitman, M. A. & Lovell, M. A. Single-base resolution mapping of 5-hydroxymethylcytosine modifications in hippocampus of Alzheimer\u2019s disease subjects. J. Mol. Neurosci. 63, 185\u2013197 (2017).","journal-title":"J. Mol. Neurosci."},{"key":"21330_CR61","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1042\/CS20050163","volume":"110","author":"MV Chao","year":"2006","unstructured":"Chao, M. V., Rajagopal, R. & Lee, F. S. Neurotrophin signalling in health and disease. Clin. Sci. Lond. 110, 167\u2013173 (2006).","journal-title":"Clin. Sci. Lond."},{"key":"21330_CR62","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ygeno.2017.02.004","volume":"109","author":"Z Mortezaei","year":"2017","unstructured":"Mortezaei, Z., Lanjanian, H. & Masoudi-Nejad, A. Candidate novel long noncoding RNAs, MicroRNAs and putative drugs for Parkinson\u2019s disease using a robust and efficient genome-wide association study. Genomics 109, 158\u2013164 (2017).","journal-title":"Genomics"},{"key":"21330_CR63","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1242\/jcs.048975","volume":"122","author":"J Chang","year":"2009","unstructured":"Chang, J., Baloh, R. H. & Milbrandt, J. The NIMA-family kinase Nek3 regulates microtubule acetylation in neurons. J. Cell Sci. 122, 2274\u20132282 (2009).","journal-title":"J. Cell Sci."},{"key":"21330_CR64","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.febslet.2005.11.059","volume":"580","author":"J-J Pei","year":"2006","unstructured":"Pei, J. -J. et al. P70 S6 kinase mediates tau phosphorylation and synthesis. FEBS Lett. 580, 107\u2013114 (2006).","journal-title":"FEBS Lett."},{"key":"21330_CR65","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JAD-2008-14405","volume":"14","author":"J-J Pei","year":"2008","unstructured":"Pei, J. -J., Bj\u00f6rkdahl, C., Zhang, H., Zhou, X. & Winblad, B. p70 S6 kinase and tau in Alzheimer\u2019s disease. J. Alzheimers Dis. 14, 385\u2013392 (2008).","journal-title":"J. Alzheimers Dis."},{"key":"21330_CR66","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.febslet.2007.11.078","volume":"582","author":"X-W Zhou","year":"2008","unstructured":"Zhou, X. -W., Tanila, H. & Pei, J. -J. Parallel increase in p70 kinase activation and tau phosphorylation (S262) with Abeta overproduction. FEBS Lett. 582, 159\u2013164 (2008).","journal-title":"FEBS Lett."},{"key":"21330_CR67","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s41048-019-0086-2","volume":"5","author":"M Wu","year":"2019","unstructured":"Wu, M. et al. Identification of key genes and pathways for Alzheimer\u2019s disease via combined analysis of genome-wide expression profiling in the hippocampus. Biophys. Rep. 5, 98\u2013109 (2019).","journal-title":"Biophys. Rep."},{"key":"21330_CR68","doi-asserted-by":"publisher","first-page":"14042","DOI":"10.1523\/JNEUROSCI.2781-15.2015","volume":"35","author":"A Caccamo","year":"2015","unstructured":"Caccamo, A. et al. Reducing ribosomal protein S6 kinase 1 expression improves spatial memory and synaptic plasticity in a mouse model of Alzheimer\u2019s disease. J. Neurosci. 35, 14042\u201314056 (2015).","journal-title":"J. Neurosci."},{"key":"21330_CR69","doi-asserted-by":"crossref","unstructured":"Hernandez, I. et al. A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy. Sci. Transl. Med. 11, eaat3005 (2019).","DOI":"10.1126\/scitranslmed.aat3005"},{"key":"21330_CR70","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21330_CR71","doi-asserted-by":"publisher","first-page":"13548","DOI":"10.1038\/s41598-019-49795-6","volume":"18","author":"S Seddighi","year":"2019","unstructured":"Seddighi, S, Houck, A. L., Rowe J. B. & Pharoah P. D. P. Evidence of a causal association between cancer and alzheimer\u2019s disease: a mendelian randomization analysis. Sci Rep. 18, 13548 (2019).","journal-title":"Sci Rep"},{"key":"21330_CR72","doi-asserted-by":"publisher","first-page":"e196160","DOI":"10.1001\/jamanetworkopen.2019.6160","volume":"2","author":"M Ospina-Romero","year":"2019","unstructured":"Ospina-Romero, M. et al. Rate of memory change before and after cancer diagnosis. JAMA Netw. Open 2, e196160 (2019).","journal-title":"JAMA Netw. Open"},{"key":"21330_CR73","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41591-019-0695-9","volume":"26","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer\u2019s disease. Nat. Med. 26, 131\u2013142 (2020).","journal-title":"Nat. Med."},{"key":"21330_CR74","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.celrep.2019.09.066","volume":"29","author":"OH Tam","year":"2019","unstructured":"Tam, O. H. et al. Postmortem cortex samples identify distinct molecular subtypes of ALS: retrotransposon activation, oxidative stress, and activated glia. Cell Rep. 29, 1164\u20131177.e5 (2019).","journal-title":"Cell Rep."},{"key":"21330_CR75","doi-asserted-by":"publisher","first-page":"117906951983069","DOI":"10.1177\/1179069519830697","volume":"13","author":"TK Saldi","year":"2019","unstructured":"Saldi, T. K., Gonzales, P. K., LaRocca, T. J. & Link, C. D. Neurodegeneration, heterochromatin, and double-stranded RNA. J. Exp. Neurosci. 13, 1179069519830697 (2019).","journal-title":"J. Exp. Neurosci."},{"key":"21330_CR76","doi-asserted-by":"publisher","first-page":"16562","DOI":"10.1073\/pnas.1310249110","volume":"110","author":"B Bai","year":"2013","unstructured":"Bai, B. et al. U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer\u2019s disease. Proc. Natl Acad. Sci. USA 110, 16562\u201316567 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21330_CR77","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nature14252","volume":"518","author":"E Gjoneska","year":"2015","unstructured":"Gjoneska, E. et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer\u2019s disease. Nature 518, 365\u2013369 (2015).","journal-title":"Nature"},{"key":"21330_CR78","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481\u2013487 (2017).","journal-title":"Nature"},{"key":"21330_CR79","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/ana.25123","volume":"83","author":"PA Boyle","year":"2018","unstructured":"Boyle, P. A. et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann. Neurol. 83, 74\u201383 (2018).","journal-title":"Ann. Neurol."},{"key":"21330_CR80","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41593-018-0175-4","volume":"21","author":"J Park","year":"2018","unstructured":"Park, J. et al. A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer\u2019s disease. Nat. Neurosci. 21, 941\u2013951 (2018).","journal-title":"Nat. Neurosci."},{"key":"21330_CR81","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1038\/s41591-019-0597-x","volume":"25","author":"BA Dickerman","year":"2019","unstructured":"Dickerman, B. A., Garc\u00eda-Alb\u00e9niz, X., Logan, R. W., Denaxas, S. & Hern\u00e1n, M. A. Avoidable flaws in observational analyses: an application to statins and cancer. Nat. Med. 25, 1601\u20131606 (2019).","journal-title":"Nat. Med."},{"key":"21330_CR82","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.7150\/thno.21254","volume":"8","author":"X Dong","year":"2018","unstructured":"Dong, X. Current strategies for brain drug delivery. Theranostics 8, 1481\u20131493 (2018).","journal-title":"Theranostics"},{"key":"21330_CR83","doi-asserted-by":"publisher","first-page":"i192","DOI":"10.1093\/bioinformatics\/btw277","volume":"32","author":"A Srivastava","year":"2016","unstructured":"Srivastava, A., Sarkar, H., Gupta, N. & Patro, R. RapMap: a rapid, sensitive and accurate tool for mapping RNA-seq reads to transcriptomes. Bioinformatics 32, i192\u2013i200 (2016).","journal-title":"Bioinformatics"},{"key":"21330_CR84","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nmeth.4220","volume":"14","author":"V Svensson","year":"2017","unstructured":"Svensson, V. et al. Power analysis of single cell RNA-sequencing experiments. Nat. Methods 14, 381\u2013387 (2017).","journal-title":"Nat. Methods"},{"key":"21330_CR85","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.csda.2010.11.018","volume":"55","author":"A Airola","year":"2011","unstructured":"Airola, A., Pahikkala, T., Waegeman, W., De Baets, B. & Salakoski, T. An experimental comparison of cross-validation techniques for estimating the area under the ROC curve. Comput Stat. Data Anal. 55, 1828\u20131844 (2011).","journal-title":"Comput Stat. Data Anal."},{"key":"21330_CR86","doi-asserted-by":"publisher","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","volume":"45","author":"A Gaulton","year":"2017","unstructured":"Gaulton, A. et al. The ChEMBL database in 2017. Nucleic Acids Res. 45, D945\u2013D954 (2017).","journal-title":"Nucleic Acids Res."},{"key":"21330_CR87","doi-asserted-by":"publisher","unstructured":"Rodriguez, S. et al. Data: machine learning identifies candidates for drug repurposing in Alzheimer\u2019s disease. https:\/\/www.synapse.org\/DRIADhttps:\/\/doi.org\/10.7303\/syn18488020 (2021).","DOI":"10.7303\/syn18488020"},{"key":"21330_CR88","doi-asserted-by":"publisher","unstructured":"Rodriguez, S. et al. Machine learning identifies candidates for drug repurposing in Alzheimer\u2019s disease. https:\/\/github.com\/labsyspharm\/DRIADhttps:\/\/doi.org\/10.5281\/zenodo.4432966 (2021).","DOI":"10.5281\/zenodo.4432966"},{"key":"21330_CR89","doi-asserted-by":"crossref","unstructured":"Potter, S. & Murrell, P. grImport2: importing \u2018SVG\u2019 graphics. https:\/\/cran.r-project.org\/package=grImport2\u00a0(2019).","DOI":"10.32614\/CRAN.package.grImport2"},{"key":"21330_CR90","unstructured":"Potter, S. & Murrell, P. gridSVG: export \u2018grid\u2019 graphics as SVG.\u00a0https:\/\/cran.r-project.org\/package=gridSVG (2019)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21330-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21330-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21330-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T05:39:11Z","timestamp":1724477951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21330-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21330"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21330-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.15.098749","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.3410\/f.739565216.793584785","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"15 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests. P.K.S. is a member of the SAB or Board of Directors of Applied Biomath, RareCyte, NanoString and Glencoe Software and has equity in some of these companies. In the last 5 years, the Sorger lab has received research funding from Novartis and Merck. P.K.S. declares that none of these relationships are directly or indirectly related to the content of this manuscript. B.T.H. has stock in Novartis and Dewpoint. N.T.J. is an employee of H3 Biomedicine, a subsidiary of Eisai Inc. that develops therapies for Alzheimer\u2019s. S.R., P.K.S., M.W.A., and A.S. are inventors on a patent application (WO\/2017\/173451) for novel targets in neurodegenerative diseases. All other authors (C.H., P.T., N.M., S.B., K.E., G.Z.) declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1033"}}